THE UK Government’s “woefully inadequate” record-keeping means it is “impossible” to have confidence that hundreds of millions of pounds of Covid-19 testing contracts with Randox were awarded properly, MPs have warned.
In a highly critical report, the Commons Public Accounts Committee (PAC), which assesses value for public money, accused the Department of Health and Social Care (DHSC) of failing in its duties to be “transparent” about meetings that ministers had with Randox Laboratories.
The MPs also said “basic civil service practices to document contract decision-making were not followed”.
Labour chairwoman of the Public Accounts Committee, Dame Meg Hillier, said the NAO (National Audit Office) has been careful to stress that it has not seen any evidence that the Government’s contracts with Randox were awarded improperly.
However she added: “But then, in the case of the hundreds of millions of pounds of contracts awarded to Randox there was precious little evidence to see.”
SNP MP Martyn Day said the public deserved answers over why UK ministers did nothing to ensure proper contracts were kept.
He said: “This all stinks to the high heavens, and of course it’s not the first time the Tories’ awarding of Covid contracts has come into question.
“It’s clear that these incidents are not in any way isolated, the UK Government's record of sleaze and scandal has been well documented throughout Boris Johnson’s tenure - it's endemic within the Conservative Party.
“The public deserve answers over why Randox, a firm that failed to deliver expected levels of testing capacity against its first contract, were awarded a further £328 million of public money and why the government did nothing to ensure proper records were kept.”
“He may be going, but Boris Johnson and his cronies will be followed for decades by his legacy of sleaze and corruption at all levels of his government which he seems to have empowered to engage in the dodgy activities we hear about far too often.”
Between January 2020 and December 2021, the DHSC and Public Health England (PHE) awarded 22 testing contracts to health company Randox, or its strategic partner, Qnostics, with a maximum value of £776.9 million.
However, the cross-party committee of MPs said it is “impossible to have confidence” that the contracts – many without competition – “were awarded properly”.
The report stated: “Woefully inadequate record-keeping by the department makes it impossible to have confidence that all its contracts with Randox were awarded properly.”
It added: “Even allowing for the exceptional circumstances at the start of the pandemic, basic civil service practices to document contract decision-making were not followed.
“The department further failed in its duties to be transparent about meetings that its ministers had with Randox.
“The potential for conflicts of interest was obvious, but the department neglected to explicitly consider conflicts of interest in its awarding of contracts to Randox.”
Furthermore, the report highlighted that following the initial £132m contract – awarded with no competition and without any performance measures – Randox struggled to deliver the expected level of testing capacity.
Despite this, the Government “still awarded Randox a contract extension worth £328m seven months later, again without competition”.
Randox saw a hundred-fold increase in its profits in the year to June 2021 – but the Government did not consider supplier profit margins or the potential for excess profits in its decision-making on the contracts, MPs said.
The report made several recommendations, including suggesting that the DHSC should, in its Treasury minute response, set out how “it intends to strengthen its transparency processes and ensure that it enforces requirements and takes action where they are not followed”.
A Randox spokesperson said the PAC report was “deeply flawed and wrong in assumptions it makes and the conclusions it draws” and said the firm had issued a legal complaint.
“As the UK’s largest diagnostic company, with four decades of experience, over 2000 professional staff on hand at the start of the pandemic and more than £350m of prior investment in diagnostic and engineering innovation, Randox was uniquely situated to respond to the national need when Covid-19 emerged in early 2020,” the spokesman said.
“In supporting the UK’s urgent requirement for coronavirus testing, Randox reacted with speed, efficiency and flexibility in delivering value.”
The spokesperson said the firm processed over 25m samples and “played a crucial role in keeping vital elements of the UK economy functioning during lockdowns”.
Taking aim at the committee, he said: “At no stage, either during its deliberations or in its preparation of this report, did the PAC make any contact whatsoever with Randox.
“Consequently many elements of its report relating to Randox are false, based as they are, on wrong and unchecked assumptions about the company.”
